Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-10-21
2008-03-11
Schultz, J. Douglas (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C536S023100, C514S04400A
Reexamination Certificate
active
07342111
ABSTRACT:
Provided are methods for the identification of novel genes involved in a variety of cellular processes, including retinal degeneration, retinal disease, cancer, memory and learning, amylotropic lateral sclerosis, and methods for the identification of the function of a variety of genes and gene fragments of unknown function. The genes thus identified, as well as the compositions used in the identification methods, are also provided.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4883750 (1989-11-01), Whiteley et al.
patent: 4987071 (1991-01-01), Cech et al.
patent: 5037746 (1991-08-01), Cech et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116742 (1992-05-01), Cech et al.
patent: 5297721 (1994-03-01), Schneider et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5354855 (1994-10-01), Cech et al.
patent: 5455166 (1995-10-01), Walker
patent: 5498539 (1996-03-01), Harrison et al.
patent: 5631359 (1997-05-01), Chowrira et al.
patent: 5639655 (1997-06-01), Thompson et al.
patent: 5646020 (1997-07-01), Swiggen et al.
patent: 5646031 (1997-07-01), DeYoung
patent: 5648211 (1997-07-01), Fraiser et al.
patent: 5712124 (1998-01-01), Walker
patent: 5744311 (1998-04-01), Fraiser et al.
patent: 6225291 (2001-05-01), Lewin et al.
patent: 6943153 (2005-09-01), Manning, Jr. et al.
patent: 2001/0034054 (2001-10-01), Dwarki et al.
patent: 2001/0051611 (2001-12-01), Srivastava et al.
patent: 2002/0132336 (2002-09-01), Dwarki et al.
patent: 2002/0194630 (2002-12-01), Manning, Jr. et al.
patent: 2003/0166284 (2003-09-01), Srivastava et al.
patent: 0360257 (1990-03-01), None
patent: 0320308 (1993-11-01), None
patent: 0329822 (1994-06-01), None
patent: 2202328 (1988-09-01), None
patent: WO87/06270 (1987-10-01), None
patent: WO88/10315 (1988-12-01), None
patent: WO89/06700 (1989-07-01), None
patent: WO89/09284 (1989-10-01), None
patent: WO90/07641 (1990-07-01), None
patent: WO91/03162 (1991-03-01), None
patent: WO92/07065 (1992-04-01), None
patent: WO93/15187 (1993-08-01), None
patent: WO93/23569 (1993-11-01), None
patent: WO94/02595 (1994-02-01), None
patent: WO94/13688 (1994-06-01), None
patent: WO95/04142 (1995-02-01), None
patent: WO97/11169 (1997-03-01), None
patent: WO97/32024 (1997-09-01), None
patent: WO98/48009 (1998-10-01), None
patent: WO98/48027 (1998-10-01), None
patent: WO 00/54813 (2000-09-01), None
patent: WO 02/24234 (2002-03-01), None
patent: WO 02/088320 (2002-11-01), None
Afzal et al., “Reduction on Preretinal Neovascularization by Ribozymes that Cleave the A2BAdrenosine Receptor mRNA,”Circulation Research, Sep. 23, 2003.
Alfione et al., “In vivo model of adeno-associated virus vector persistence and rescue,”Journal of Virology, 70:3235-3241, 1996.
Altschuler et al., “A method for generating transcripts defined with 5′ and 3′ termini by autolytic processing,”Gene, 122:85-90, 1992.
Al-Ubaidi et al., “Photoreceptor degeneration induced by the expression of simian virus 40 large tumor antigen in the retina of transgenic mice,”Proc.Natl. Acad. Sci.USA, 89:1194-1198, 1992.
Bergsland et al., “Update on Clinical Trials Targeting Vascular Endothelial Growth Factor in Cancer,”Am. J. Health Syst. Pharm., 61(5): S12-S20, Nov. 2004.
Blalock et al., “Hammerhead ribozyme targeting connective tissue growth factor mRNA blocks transforming growth factor-beta mediated cell proliferation,”Experimental Eye Research, 78: 1127-1136, 2004.
Cech, “Self-splicing of Group I introns,”Annu. Rev. Biochem, 59:543-568, 1990.
Chakravathy et al., “Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes,”Curr. Eye Res., 14(4):285-294, 1995.
Chen et al., “The human blue opsin promoter directs transgene expression in short-wave cones and bipolar cells in the mouse retina,”Proc. Natl. Acad. Sci. USA, 91(7):2611-2615, 1994.
Christoffersen et al., “Ribozymes as Human Therapeutic Agents,”J. Med. Chem., 38: 2023-2037, Jun. 1995.
Chiu et al., “A sequence upstream of the mouse blue visual pigment gene directs blue cone-specific transgene expression in mouse retinas,”Visual Neuroscience, 11(4):773-780, 1994.
Cipolla et al., “High glucose concentrations dilate cerebral arteries and diminish myogenic tone through an endothelial mechanism,”Stroke, 28(2):405-411, 1997.
Cosentino et al., “High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells,”Circulation, 96(1):25-28, 1997.
Cordiero et al., “Molecular Therapy in Ocular Wound Healing,”BJO Online, 83: 1219-1224, 1999.
Crooke, “Another Piece in the Mosaic. Antisense and Nucleic Acid Drug Development,” 8:vii-viii, 1998.
Crystal, “Transfer of genes to humans: early lessons and obstacles to success,”Science, 270:404-410, 1995.
Daiger et al., “Correlation of phenotype with genotype in inherited retinal degeneration,”Behavioral and Brain Sciences, 18:452-467, 1995.
Desjardin et al., “Developmentally important DNA elements within the bovine opsin upstream region,”Investigative Ophthalmology&Visual Science, 37(1):154-165, 1996.
Drenser et al., “Ribozyme mediated degredation of the P23H and S334Ter mutant mRNAs associated with ADRP,”Investigative Opthalmology&Visual Science, 38(4):S441, Abstract 2085, 1997 (Annual Mtg. Of the Association for Research in Vision and Opthalmology, Fort Lauderdale, Florida, USA, May 11-196, 1997).
Drenser et al., “Ribozyme mediated destruction of an messenger-RNA causing retinitis pigmentosis,”Investigative Ophthalmology&Visual Science, 37(3):S10, Abstract 42, 1996.
Drenser et al., “Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa,”Investigative Ophthalmology&Visual Science, 39(5):681-689, 1998.
Farrar et al., “On the Genetics of Retinits Pignentosa and on Mutation-Independent Approaches to Therapeutic Intervention,”EMBO J., 21(5): 857-864, 2002.
Flannery et al., “Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus,”Proc. Natl. Acad. Sci. USA, 94(13):6916-6921, 1997.
Flotte et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector,”Proc. Natl, Acad. Sci. USA, 90(22):10613-10617, 1993.
Fritz et al., “Design and Validation of Therapeutic Hammerhead Ribozymes for Autosomal Dominant Diseases,”Methods Mol. Bio., 252: 221-36, 2004.
Fritz et al., “Designing and Characterizing Hammerhead Ribozymes for Use in AAV Vector-Mediated Retinal Gene Therapies,”Methods Enzymol., 346: 358-77, 2002.
Fritz et al., “Development of Hammerhead Ribozymes to Modulate Endogenous Gene Expression For Functional Studies,”Methods, 28(2): 276-85, Oct. 2002.
Gade et al., “Nitric oxide mediates hyperglycemia-induced defective migration in cultured endothelial cells,”Journal of Vascular Surgery, 26(2):319-326, 1997.
Gewirtz et al., “Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise,”Proc. Natl. Acad. Sci, 93: 3161-3163, Apr. 1996.
Goldstein, Ostwal and Roth, “Nitric oxide: a review of its role in retinal function and disease,”Vision Res., 36(18):2979-2994, 1996.
Gorbatyuk et al., “Knockdown of Wild-Type Mouse Rhodopsin Using an AAV Vectored Ribozyme as Part of an RNA Replacement Approach,”Mol. Vis., 11: 648:56, Aug. 29, 2005.
Hangai et al., “Inducible nitric oxide synthase in retinal ischemia-reperfusion injury,”Exp. Eye Res., 63(5):501-509, 1996.
Hauswirth et al., “Adeno-associated virus delivery of an opsin promoter driven reporter gene to the mouse and rabbit retina,”Gene Therapy, 2(Supp. 1):S2, Ab
Hauswirth William
Lewin Alfred S.
Qi Xiaoping
Bowman Amy H.
Haynes and Boone LLP
Moore Mark D.
Schultz J. Douglas
University of Florida Research Foundation Inc.
LandOfFree
Adeno-associated virus-delivered ribozyme compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adeno-associated virus-delivered ribozyme compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adeno-associated virus-delivered ribozyme compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3976509